[go: up one dir, main page]

CA2438032A1 - Derives de benzothiazole et compositions et utilisations connexes - Google Patents

Derives de benzothiazole et compositions et utilisations connexes Download PDF

Info

Publication number
CA2438032A1
CA2438032A1 CA002438032A CA2438032A CA2438032A1 CA 2438032 A1 CA2438032 A1 CA 2438032A1 CA 002438032 A CA002438032 A CA 002438032A CA 2438032 A CA2438032 A CA 2438032A CA 2438032 A1 CA2438032 A1 CA 2438032A1
Authority
CA
Canada
Prior art keywords
compound
hydrogen
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002438032A
Other languages
English (en)
Other versions
CA2438032C (fr
Inventor
William E. Klunk
Chester A. Mathis, Jr.
Yanming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Priority to CA2438032A priority Critical patent/CA2438032C/fr
Priority to US10/645,847 priority patent/US20050043523A1/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Priority to PCT/US2004/007797 priority patent/WO2004083195A1/fr
Publication of CA2438032A1 publication Critical patent/CA2438032A1/fr
Application granted granted Critical
Publication of CA2438032C publication Critical patent/CA2438032C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2438032A 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes Expired - Lifetime CA2438032C (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
PCT/US2004/007797 WO2004083195A1 (fr) 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses

Publications (2)

Publication Number Publication Date
CA2438032A1 true CA2438032A1 (fr) 2005-02-22
CA2438032C CA2438032C (fr) 2013-05-07

Family

ID=34426453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2438032A Expired - Lifetime CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes

Country Status (2)

Country Link
CA (1) CA2438032C (fr)
WO (1) WO2004083195A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373639T3 (es) 2002-12-19 2012-02-07 The Scripps Research Institute Composiciones y usos para estabilizar la transtiretina e inhibir el plegamiento anómalo de la transtiretina.
CN101198598A (zh) 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
CN101137397A (zh) 2004-07-02 2008-03-05 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
EP1937260A2 (fr) * 2005-09-16 2008-07-02 University of Pittsburgh Methode in vivo et in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
WO2007070173A2 (fr) † 2005-10-31 2007-06-21 Merck & Co., Inc. Inhibiteurs de la cetp
WO2007063946A1 (fr) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. Diagnostic et remede pour une maladie provoquee par l’aggregation et/ou le depot d’amyloide
JP2009519239A (ja) * 2005-12-01 2009-05-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾチアゾール化合物
GB0525949D0 (en) 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
WO2008108729A1 (fr) * 2007-03-06 2008-09-12 Astrazeneca Ab Nouveaux indoles 695 à substitution 2-hétéroaryle
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
WO2008134618A2 (fr) * 2007-04-27 2008-11-06 The General Hospital Corporation Nouveaux marqueurs d'imagerie pour détecter et traiter précocement les plaques amyloïdes générées par la maladie d'alzheimer et des troubles associés
PL2182988T3 (pl) 2007-08-30 2015-02-27 Ge Healthcare Ltd Kompozycja radiofarmaceutyczna
ITMC20080089A1 (it) * 2008-05-23 2008-08-22 Sparkle S R L Sintesi chimica di i-124[6-oh-bta-1-3'-i] iodine-124[2-(3'-iodo-4'-methylaminophenyl)-6-hydroxy-benzothialzole] per indagini pet e radioterapia.
WO2009155017A2 (fr) 2008-05-30 2009-12-23 Merck & Co., Inc. Nouveaux azabenzoxazoles substitués
EP2338059B1 (fr) 2008-09-23 2015-04-08 WisTa Laboratories Ltd. Ligands pour molécules de la protéine tau agglomérées
EP2341909A4 (fr) * 2008-10-31 2012-05-30 Merck Sharp & Dohme Nouveaux azabenzoxazoles substitués
SG2014013270A (en) 2011-09-16 2014-05-29 Pfizer Solid forms of a transthyretin dissociation inhibitor
DK2890700T3 (en) 2012-08-28 2018-03-12 Univ Tuebingen Medizinische Fakultaet HALOGENATED BENZOXAZINES AND THEIR USE
KR101770532B1 (ko) * 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
WO2015051188A1 (fr) * 2013-10-02 2015-04-09 Washington University Molécules hétérocycliques pour l'imagerie biomédicale et leurs applications thérapeutiques
CA2959505A1 (fr) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Sondes d'imagerie de la proteine huntingtine
CN107108534B (zh) 2014-08-29 2023-05-09 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
JP6485914B2 (ja) * 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
PT1334091E (pt) * 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
EP1381604B1 (fr) * 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique

Also Published As

Publication number Publication date
CA2438032C (fr) 2013-05-07
WO2004083195A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
CA2438032C (fr) Derives de benzothiazole et compositions et utilisations connexes
US9833458B2 (en) Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AU2011200667B2 (en) Benzothiazole derivative compounds, compositions and uses
US9134328B2 (en) Methods of using benzothiazole derivative compounds and compositions
US20120263646A1 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
US20050043523A1 (en) Benzothiazole derivative compounds, compositions and uses
HK1086270B (en) Benzothiazole derivative compounds, compositions and uses
HK1146725B (en) Thioflavin derivatives for use in the diagnosis of alzheimer's disease
HK1058041B (en) Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230822